Cyclacel's sapacitabine fails in Phase III AML trial

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) lost $1.36 (25%) to $4.05 on Thursday after its sapacitabine (CYC682) missed the primary endpoint in the pivotal Phase III SEAMLESS trial to treat newly diagnosed acute

Read the full 317 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE